Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on Karyopharm Therapeutics (NASDAQ:KPTI) but lowered the price target from $8 to $7.
August 04, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler has maintained an Overweight rating on Karyopharm Therapeutics but lowered the price target from $8 to $7.
The news is directly about Karyopharm Therapeutics. While the Overweight rating is maintained, the lowering of the price target could indicate a potential decrease in the stock's value. However, the impact is not clear cut as the Overweight rating suggests that the analyst still sees potential in the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100